Proven alternatives deliver comparable results with established safety: tirzepatide monotherapy produces 15-22% weight loss with FDA approval and extensive clinical data, while CagriSema (cagrilintide + semaglutide) delivers 15-25% weight loss with Phase 3 trial validation and clearer path to medical acceptance
The variability reflects differences in glutathione bioavailability, dosing protocols, baseline patient selenium and zinc status, and genetic factors affecting antioxidant enzyme efficiency
Rubinskii AV, Linkova NS, Chalisova NI, Noskin LA, Marchenko VN, Khavinson VK
no LD50 established even at very high doses in rodents No Hormonal Effects: Does not affect testosterone, estrogen, growth hormone, or other hormonal axes Gastric Origin: Derived from a naturally occurring human gastric protein, suggesting good biological compatibility Stability: Unusually stable in gastric acid, supporting oral administration potential Reported Effects: Anecdotal reports of fatigue, nausea in some research subjects TB-500 Safety Profile: (PMID: 20536472) Note: Published safety data is primarily available for Thymosin Beta-4
Archived from the original on 19 December 2019
